Additional IncuCyte Publications

1. Ostyn, P et al. Transient TNF regulates the self-renewing capacity of stem-like label-retaining cells in sphere and skin equivalent models of melanoma, Cell Communication and Signaling, 2014, 12(1), 52.
   
   
2. Nair, R et al. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene, 2014, 33(30), 3992-4002.
    
3. Bonuccelli, G et al. NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting stemness. Oncotarget, 2017, 8(13), 20667-20678.
    
4. Lotte, ME et al. The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells. Genes & Cancer, 2014, 5, 445-459.
    
5. Beaver, CM et al. Clonogenicity: holoclones and meroclones contain stem cells. PloS One, 2014, 9, e89834.
    
6. Tang, B et al. A Flexible Reporter System for Direct Observation and Isolation of Cancer Stem Cells. Stem Cell Reports, 2015, 4, 155-169.
    
7. Tomellini, E et al. NGF and proNGF simultaneously promote symmetric self-renewal, quiescence and EMT to enlarge the breast cancer stem cell compartment. Stem Cells, 2015, 33(2), 342-353.
    
8. Alvero, AB et al. TRX-E-002-1 induces c-jun-dependent apoptosis in ovarian cancer stem cells and prevents recurrence in vivo. Molecular Cancer Therapeutics, 15(6), 1279-1290.
    
9. Dermawan, JK et al. Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Research, 2016, 76(8), 2432-2442.
    
10. Raha, D et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Research, 2014, 74(13), 3579-3590.
     
11. Alvero, AB et al. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. Oncotarget, 2014, 5(18), 8703-8715.
     
12. Blum, W et al. Stem Cell Factor-Based Identification and Functional Properties of InVitro-Selected Subpopulations of Malignant Mesothelioma Cells. Stem Cell Reports, 2017, 8(4), 1005-1017.
     
13. Calvet, CY et al. The culture of cancer cell lines as tumorspheres does not systematically result in cancer stem cell enrichment. PloS One, 2014, 9, e89644.
     
14. Morisaki, T et al. Comparative proteomics analysis of gastric cancer stem cells. PLoS One, 9, e110736.
     
15. Puvanenthiran, S et al. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. International Journal of Oncology, 2016, 49, 1825-1838.
     
16. Redmer, T et al. The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis, 2017, 6(6), e291.
     
17. Chefetz, I et al. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle, 2013, 12(3), 511-521.
     
18. Chefetz, I et al. Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway. Cell Cycle, 2011, 10(13), 2206-2214.
    
    
19. Craveiro, V et al. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Medicine, 2013, 2(6), 751-762.
    
    
20. Matzke-Ogi, A et al. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by interference with CD44v6 Signaling. Gastroenterology, 2016, 150(2), 513-525.